Breast Cancer

For Adjuvant Trastuzumab, 6 Months Is Noninferior to 12 Months

The noninferiority phase III Persephone trial could shake up the standard of care for adjuvant trastuzumab, showing that patients with early-stage HER2-positive breast cancer...

ASCO’s Incoming President Sets Her Goals for the Next Year

With all the advances in oncology care over the past decade, the most important contribution to high-quality care remains the personal connection between oncologist and patient...

Serving as ASCO President Is One of the Best Jobs in the World

The opportunity to serve as ASCO President is the greatest honor of my professional career. It has been a pleasure and a highly rewarding experience to interact with our members...


Advertisement
Hematologic Malignancies

Upfront Use of Nelarabine Plus Chemotherapy Improves Disease-Free Survival in T-Cell Malignancies

Upfront use of nelarabine plus standard Children’s Oncology Group–augmented Berlin-Frankfurt-Münster (aBFM) chemotherapy boosted survival rates...

Breast Cancer

Endocrine Therapy: An Important Treatment Limited by Major Challenges

“Endocrine therapy remains the most effective and least toxic treatment for breast cancer, but we have many problems to solve. And there will have to be many different solutions...


More Top Stories

Issues in Oncology
Cost of Care

Levi Garraway, MD, PhD, on Drug Development and the Cost of Researching and Treating Cancer

Gynecologic Cancers

Adding Hyperthermic Intraperitoneal Chemotherapy to Cytoreductive Surgery Improves Outcomes in Advanced Ovarian Cancer

In a Dutch/Belgian phase III trial reported in TheNew England Journal of Medicine by Willemien J. van Driel, MD, PhD, of the Netherlands Cancer Institute, and colleagues, the addition of hyperthermic intraperitoneal chemotherapy (aka HIPEC) to interval cytoreductive surgery following neoadjuvant...

Advertisement

FDA Identifies Efficacy Issue in Clinical Trials of Pembrolizumab or Atezolizumab as Monotherapy in Urothelial Cancer With Low Expression of PD-L1

On May 18, the U.S. Food and Drug Administration (FDA) alerted health-care professionals, oncology clinical investigators, and the public about decreased survival associated with the use of pembrolizumab (Keytruda) or atezolizumab (Tecentriq) as monotherapy in clinical trials to treat patients with ...

Issues in Oncology
Cost of Care

Amy Kapczynski, JD, on Drug Development and the Cost of Researching and Treating Cancer

Treatment Centers Authorized to Administer CAR T-Cell Therapy

The following medical facilities are certified to administer chimeric antigen receptor (CAR) T-cell therapy to eligible patients (as of May 16, 2018). However, not all of the centers administer both tisagenlecleucel (Kymriah) and axicabtagene ciloleucel (Yescarta). To identify the centers...

Symptom Management

ASCO Clinical Practice Guideline on Managing Immune-Related Adverse Events: Next Big Step for Immune Checkpoint Inhibitors

The publication of the ASCO clinical practice guideline for the management of immune therapy–related adverse events—reviewed in this issue of The ASCO Post—represents an important next step in the incorporation of checkpoint blocking antibodies as standard cancer treatment modalities.1 The U.S....

PARP Inhibitor Shows Promise in Patients With BRCA-Mutated Pancreatic Cancer

A targeted therapy that has been effective in fighting ovarian cancer in women, including those with BRCA1 and BRCA2 mutations, may also help patients with aggressive pancreatic cancer who harbor these mutations and have few or no other treatment options. An international team of researchers was...

Issues in Oncology

Blase Polite, MD, on Cancer, Health Justice, and Disparities

New Updates to Common Rule for Researchers

THIS PAST January, the Department of Health and Human Services (HHS), along with more than a dozen other federal agencies, finalized updates to the Common Rule, which protects human participants in biomedical research. This marked the first time that the Common Rule has been updated in nearly 3...

Advertisement

Circulating Tumor Cells and Benefit of Adjuvant Radiotherapy in Early Breast Cancer

In a study reported in JAMA Oncology, Goodman et al found that adjuvant radiotherapy was associated with better outcome in patients with early breast cancer who had detectable circulating tumor cells (CTCs). Study Details The analysis included data from patients with stage pT1 to pT2 and pN0 to...


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.